Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.

Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.

2.

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS.

J Immunother Cancer. 2019 Aug 10;7(1):214. doi: 10.1186/s40425-019-0682-1.

3.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.

J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.

4.

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.

Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT.

Int J Radiat Oncol Biol Phys. 2019 Jul 2. pii: S0360-3016(19)33428-5. doi: 10.1016/j.ijrobp.2019.06.2540. [Epub ahead of print]

PMID:
31276776
5.

Viral Targeting of Non-Muscle-Invasive Bladder Cancer and Priming of Antitumor Immunity Following Intravesical Coxsackievirus A21.

Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS.

Clin Cancer Res. 2019 Jul 4. doi: 10.1158/1078-0432.CCR-18-4022. [Epub ahead of print]

PMID:
31273010
6.

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Müller LME, Holmes M, Michael JL, Scott GB, West EJ, Scott KJ, Parrish C, Hall K, Stäble S, Jennings VA, Cullen M, McConnell S, Langton C, Tidswell EL, Shafren D, Samson A, Harrington KJ, Pandha H, Ralph C, Kelly RJ, Cook G, Melcher AA, Errington-Mais F.

J Immunother Cancer. 2019 Jul 1;7(1):164. doi: 10.1186/s40425-019-0632-y.

7.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

8.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
9.

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL.

J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.

10.

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.

Jennings VA, Scott GB, Rose AMS, Scott KJ, Migneco G, Keller B, Reilly K, Donnelly O, Peach H, Dewar D, Harrington KJ, Pandha H, Samson A, Vile RG, Melcher AA, Errington-Mais F.

Mol Ther. 2019 Jun 5;27(6):1139-1152. doi: 10.1016/j.ymthe.2019.04.008. Epub 2019 Apr 14.

11.

Principal component analysis fosr fast and model-free denoising of multi b-value diffusion-weighted MR images.

Gurney-Champion OJ, Collins DJ, Wetscherek A, Rata M, Klaassen R, van Laarhoven HWM, Harrington KJ, Oelfke U, Orton MR.

Phys Med Biol. 2019 May 17;64(10):105015. doi: 10.1088/1361-6560/ab1786.

PMID:
30965296
12.

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.

Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Smith KK, Harris RS, Coffey M, Pulido JS, Pandha H, Selby PJ, Harrington KJ, Melcher A, Vile RG.

Cancer Immunol Res. 2019 May;7(5):828-840. doi: 10.1158/2326-6066.CIR-18-0013. Epub 2019 Apr 2.

PMID:
30940643
13.

Improving Attitudes and Perceptions About End-of-Life Nursing on a Hospital-Based Palliative Care Unit.

Harrington KJ, Affronti ML, Schneider SM, Razzak AR, Smith TJ.

J Hosp Palliat Nurs. 2019 Aug;21(4):272-279. doi: 10.1097/NJH.0000000000000523.

PMID:
30893285
14.

PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.

Smith HG, Mansfield D, Roulstone V, Kyula-Currie JN, McLaughlin M, Patel RR, Bergerhoff KF, Paget JT, Dillon MT, Khan A, Melcher A, Thway K, Harrington KJ, Hayes AJ.

Clin Cancer Res. 2019 Jun 1;25(11):3443-3454. doi: 10.1158/1078-0432.CCR-18-3767. Epub 2019 Mar 18.

PMID:
30885937
15.

ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.

Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, Foo S, Bozhanova G, Ragulan C, Fontana E, Desai K, Wilkins AC, Sadanandam A, Melcher A, McLaughlin M, Harrington KJ.

Clin Cancer Res. 2019 Jun 1;25(11):3392-3403. doi: 10.1158/1078-0432.CCR-18-1821. Epub 2019 Feb 15.

PMID:
30770349
16.

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.

Gutzmer R, Harrington KJ, Hoeller C, Lebbé C, Malvehy J, Öhrling K, Downey G, Dummer R.

Eur J Dermatol. 2018 Dec 1;28(6):736-749. doi: 10.1684/ejd.2018.3447. Review.

PMID:
30698145
17.

The immunological consequences of radiation-induced DNA damage.

Wilkins AC, Patin EC, Harrington KJ, Melcher AA.

J Pathol. 2019 Apr;247(5):606-614. doi: 10.1002/path.5232. Epub 2019 Feb 15. Review.

PMID:
30632153
18.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Erratum in: Lancet. 2019 Jan 12;393(10167):132.

PMID:
30509740
19.

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.

Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ.

Clin Cancer Res. 2019 Jan 15;25(2):487-495. doi: 10.1158/1078-0432.CCR-18-1539. Epub 2018 Oct 16.

PMID:
30327312
20.

APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.

Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG.

Mol Ther Oncolytics. 2018 Aug 29;11:1-13. doi: 10.1016/j.omto.2018.08.003. eCollection 2018 Dec 21.

21.

Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.

Burley TA, Da Pieve C, Martins CD, Ciobota DM, Allott L, Oyen WJG, Harrington KJ, Smith G, Kramer-Marek G.

J Nucl Med. 2019 Mar;60(3):353-361. doi: 10.2967/jnumed.118.216069. Epub 2018 Sep 13.

22.

Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT.

Harrington KJ.

Clin Cancer Res. 2019 Jan 1;25(1):3-5. doi: 10.1158/1078-0432.CCR-18-1796. Epub 2018 Aug 9.

PMID:
30093447
23.

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Dillon MT, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C, Saunders M, Banerji U, Clack G, Smith SA, Spicer JF, Forster MD, Harrington KJ.

Clin Transl Radiat Oncol. 2018 Jun 8;12:16-20. doi: 10.1016/j.ctro.2018.06.001. eCollection 2018 Aug.

24.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ.

Front Oncol. 2018 Jul 13;8:245. doi: 10.3389/fonc.2018.00245. eCollection 2018.

25.

Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.

Tree AC, Jones K, Hafeez S, Sharabiani MTA, Harrington KJ, Lalondrelle S, Ahmed M, Huddart RA.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1168-1171. doi: 10.1016/j.ijrobp.2018.04.070. Epub 2018 May 4.

26.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

27.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

28.

An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.

Henderson DR, Murray JR, Gulliford SL, Tree AC, Harrington KJ, Van As NJ.

Clin Oncol (R Coll Radiol). 2018 Sep;30(9):539-547. doi: 10.1016/j.clon.2018.05.001. Epub 2018 May 25.

PMID:
29807801
29.

NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas.

Agaimy A, Fonseca I, Martins C, Thway K, Barrette R, Harrington KJ, Hartmann A, French CA, Fisher C.

Am J Surg Pathol. 2018 Jul;42(7):877-884. doi: 10.1097/PAS.0000000000001046. Review.

30.

Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer.

Henderson DR, Tree AC, Harrington KJ, van As NJ.

Medicines (Basel). 2018 Apr 5;5(2). pii: E32. doi: 10.3390/medicines5020032.

31.

Seasonal micro-migration in a farm-island population of striated caracaras (Phalcoboenus australis) in the Falkland Islands.

Harrington KJ, Pole-Evans S, Reeves M, Bechard M, Bobowski M, Barber DR, Rexer-Huber K, Lecomte N, Bildstein KL.

Mov Ecol. 2018 Mar 30;6:4. doi: 10.1186/s40462-018-0122-8. eCollection 2018.

32.

Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.

Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM.

Radiother Oncol. 2018 Apr;127(1):43-48. doi: 10.1016/j.radonc.2018.02.002. Epub 2018 Mar 7.

PMID:
29525412
33.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

34.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

35.

Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.

Burley TA, Mączyńska J, Shah A, Szopa W, Harrington KJ, Boult JKR, Mrozek-Wilczkiewicz A, Vinci M, Bamber JC, Kaspera W, Kramer-Marek G.

Int J Cancer. 2018 Jun 1;142(11):2363-2374. doi: 10.1002/ijc.31246. Epub 2018 Jan 19.

36.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

37.

MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy.

Gurney-Champion OJ, McQuaid D, Dunlop A, Wong KH, Welsh LC, Riddell AM, Koh DM, Oelfke U, Leach MO, Nutting CM, Bhide SA, Harrington KJ, Panek R, Newbold KL.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316. doi: 10.1016/j.ijrobp.2017.10.016. Epub 2017 Oct 16.

38.

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.

Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21.

39.

International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.

Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT.

Radiother Oncol. 2018 Jan;126(1):25-36. doi: 10.1016/j.radonc.2017.10.032. Epub 2017 Nov 15.

PMID:
29153464
40.

A practical guide to the handling and administration of talimogene laherparepvec in Europe.

Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, Dummer R.

Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017. Review.

41.

Warthin Tumor-Like Mucoepidermoid Carcinoma.

Heatley N, Harrington KJ, Thway K.

Int J Surg Pathol. 2018 Feb;26(1):31-33. doi: 10.1177/1066896917724889. Epub 2017 Aug 9.

PMID:
28793830
42.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

43.

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, Licitra L.

Front Oncol. 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072. eCollection 2017. Review.

44.

The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.

Richards TM, Hurley T, Grove L, Harrington KJ, Carpenter GH, Proctor GB, Nutting CM.

Oral Dis. 2017 Oct;23(7):990-1000. doi: 10.1111/odi.12686. Epub 2017 Jun 5.

45.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331. doi: 10.18632/oncotarget.15971. Review.

46.

Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.

Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d'Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL.

Clin Cancer Res. 2017 Aug 1;23(15):4233-4241. doi: 10.1158/1078-0432.CCR-16-1209. Epub 2017 Mar 17.

47.

The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Br J Radiol. 2017 Mar;90(1071):20160768. doi: 10.1259/bjr.20160768. Review.

48.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

49.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

50.

Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.

Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):263-273. doi: 10.1016/j.clon.2016.12.001. Epub 2017 Jan 3.

Supplemental Content

Loading ...
Support Center